<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171480</url>
  </required_header>
  <id_info>
    <org_study_id>2017H0195</org_study_id>
    <nct_id>NCT03171480</nct_id>
  </id_info>
  <brief_title>Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia</brief_title>
  <acronym>NOPE</acronym>
  <official_title>Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial (RCT) of nitric-oxide donor (NOD) isosorbide mononitrate (IMN)
      versus placebo as an adjuvant to misoprostol/ intra-cervical Foley bulb for induction of
      labor to decrease rate of cesarean deliveries in pregnancies complicated by preeclampsia
      (≥24/0 weeks' gestation)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a double blinded, placebo controlled, randomized clinical
      trial of patients undergoing induction of labor for preeclampsia. Once the decision to induce
      will be taken, the participants will be randomized to receive either intravaginal IMN (40mg)
      or identical appearing placebo placed every 4hrs in the posterior vaginal fornix X 3 doses.
      IMN or placebo will be discontinued when active labor occurs or when the physician decides to
      proceed with augmentation with oxytocin or AROM. Participants will be induced using the
      investigators routine induction agents, Misoprostol (25 mcg every 4 hrs for maximum of 6
      doses) and an intra-cervical foley bulb will be inserted with 2nd dose of IMN or placebo.
      Regarding management of labor, physician decides when to proceed with augmentation with
      oxytocin or AROM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A double blinded, placebo controlled, randomized clinical trial of patients undergoing induction of labor for preeclampsia. Study drug or identical appearing placebo will be delivered to labor floor by pharmacist, after randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cesarean delivery rate</measure>
    <time_frame>3 years</time_frame>
    <description>Inductions that delivery by cesarean section</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start of induction to delivery</measure>
    <time_frame>3 years</time_frame>
    <description>Time frame from when medication is administered to when delivery occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of placental abruption, use of anti-hypertensives, maternal hypotension and uterine hyperstimulation, atony, meconium stained fluid</measure>
    <time_frame>3 years</time_frame>
    <description>Looking at different adverse outcomes during delivery that maybe associated with side effects of study drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Labor, Premature</condition>
  <arm_group>
    <arm_group_label>Monoket pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The pharmacy has compounded an identical appearing placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monoket Pill</intervention_name>
    <description>Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor</description>
    <arm_group_label>Monoket pill</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Isosorbide mononitrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women older than 18 years at the time of induction of labor with the ability to give
             informed consent

          -  Induction of labor for clinical diagnosis of preeclampsia

          -  Unfavorable cervix (Bishop's score of less than 6)

          -  Cervical dilation 2cm or less

          -  Singleton

          -  Gestational age ≥ 24 weeks

          -  English speaking

        Exclusion Criteria:

          -  • Contraindication to vaginal delivery

               -  Contraindication to misoprostol

               -  Fetal Demise

               -  Major fetal anomaly

               -  Non-english speaking women

               -  HIV

               -  Medical conditions requiring assisted second stage

               -  Category III tracing

               -  Eclampsia

               -  Hemolysis Elevated Liver enzymes Low Platelets syndrome

               -  DIC or active hemorrhage before randomization

               -  Hypersensitivity to isosorbide mononitrate

               -  Isosorbide mononitrate should not be used in cases of acute myocardial infarction
                  with low filling pressure, acute circulatory failure (shock, vascular collapse),
                  or hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, low
                  cardiac filling pressures, aortic/mitral valve stenosis and diseases associated
                  with a raised intra-cranial pressure e.g following a head trauma and including
                  cerebral hemorrhage.

               -  Isosorbide mononitrate should not be used in patients with severe anemia, severe
                  hypotension, closed angle glaucoma or severe hypovolaemia.

               -  Isosorbide mononitrate tablets contain lactose and therefore patients with rare
                  hereditary problems of galactose intolerance, the Lapp lactase deficiency or
                  glucose-galactose malabsorption should not take this medicine.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only pregnant women with preeclampsia</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara Rood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State Wexner Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Rood, MD</last_name>
    <phone>4403210264</phone>
    <email>kara.rood@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State Medical Center Labor and Delivery Unit</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Rood, MD</last_name>
      <phone>440-321-0264</phone>
      <email>kara.rood@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Frances Johnson, RN</last_name>
      <phone>614-293-5632</phone>
      <email>frances.johnson@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kara M Rood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buhimschi I, Ali M, Jain V, Chwalisz K, Garfield RE. Differential regulation of nitric oxide in the rat uterus and cervix during pregnancy and labour. Hum Reprod. 1996 Aug;11(8):1755-66.</citation>
    <PMID>8921128</PMID>
  </reference>
  <reference>
    <citation>Ghosh A, Lattey KR, Kelly AJ. Nitric oxide donors for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2016 Dec 5;12:CD006901. doi: 10.1002/14651858.CD006901.pub3. Review.</citation>
    <PMID>27918616</PMID>
  </reference>
  <reference>
    <citation>Chanrachakul B, Herabutya Y, Punyavachira P. Randomized trial of isosorbide mononitrate versus misoprostol for cervical ripening at term. Int J Gynaecol Obstet. 2002 Aug;78(2):139-45.</citation>
    <PMID>12175715</PMID>
  </reference>
  <reference>
    <citation>El-Khayat W, Alelaiw H, El-kateb A, Elsemary A. Comparing vaginal misoprostol versus Foley catheter plus vaginal isosorbide mononitrate for labor induction. J Matern Fetal Neonatal Med. 2016;29(3):487-92. doi: 10.3109/14767058.2015.1007036. Epub 2015 Feb 19.</citation>
    <PMID>25694257</PMID>
  </reference>
  <reference>
    <citation>Thomson AJ, Lunan CB, Cameron AD, Cameron IT, Greer IA, Norman JE. Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial. Br J Obstet Gynaecol. 1997 Sep;104(9):1054-7.</citation>
    <PMID>9307534</PMID>
  </reference>
  <results_reference>
    <citation>Collingham JP, Fuh KC, Caughey AB, Pullen KM, Lyell DJ, El-Sayed YY. Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial. Obstet Gynecol. 2010 Jul;116(1):121-6. doi: 10.1097/AOG.0b013e3181e408f2.</citation>
    <PMID>20567177</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kara M Rood, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

